Smoldering Myeloma Treatments

Treatments in Development

The following is a list of treatments in development for smoldering myeloma that are currently recruiting myeloma patients in the United States. You can use the buttons below to filter by diagnosis and sort the listings by name, distance as well as active number of trials.


Other ways to search
Find a trial that's right for you by personalizing your search.
Browse our myeloma treatment center directory to find a myeloma specialist near you.

Sort By Distance

Need Help?

Call SparkCures and one of our clinical trial specialists will help answer your questions.

(888) 828-2206

Atezolizumab
Atezolizumab is a new drug being tested in myeloma. It targets a protein called PDL-1 which is normally involved in dampening the immune response. This increases the activity of the immune system to recognize and destroy myeloma cells.
Autologous Transplant
Autologous Transplant is a type of stem cell transplant that utilizes the patient's pre-collected own stem cell to rescue the bone marrow from the toxic effect of a very high dose chemotherapy.
Carfilzomib (Kyprolis)
Carfilzomib is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It is approved for use with lenalidomide and dexamethasone for the treatment of relapsed multiple myeloma in patients who have received one to three prior lines of therapy.
Daratumumab (Darzalex)
Daratumumab is a drug used for the treatment of multiple myeloma. It is for use in people who have multiple myeloma who have already received at least one prior therapy. It is given as an injection into a vein through an IV.
Durvalumab
Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics. Durvalumab is being developed, alongside other immunotherapies, to strengthen the patient's immune system and attack the cancer.
Ibrutinib (Imbruvica)
Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.
Isatuximab
SAR650984 is a humanized IgG1 monoclonal antibody that binds to CD38+ cells, triggerring antitumoral antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC) and tumor programmed cell death.
Ixazomib (Ninlaro)
Ixazomib is an oral proteasome inhibitor that may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Lenalidomide (Revlimid)
Lenalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is given as an oral medication.
Nivolumab
Normally, your immune system helps defend against internal threats, such as cancer, using specialized immune cells called T cells. Some types of cancer cells present a protein called PD-L1, which interacts with the PD-1 receptor on your T cells. This can deactivate your T cells and prevent them from recognizing and attacking the cancer. Nivolumab blocks the PD-1 receptor on T cells and can halt the effects on PD-L1 on T cells, allowing them to be active and do their job.
PVX-410
PVX-410 is a vaccine that can stimulate the immune system to induce a cytotoxic T-lymphocyte response against the four myeloma-specific antigens.